A rare cause of chronic lymphadenopathy with pancytopenia in an infant

Jagdish Ashok Kathwate¹, V Sumitra¹, K Shilpa¹, S S Prabhu¹


(Key words: Cytopenia; lymphadenopathy; autoimmune lymphoproliferative syndrome; double negative T cells)

Introduction

Autoimmune lymphoproliferative syndrome (ALPS) is the first human disease whose aetiology has been attributed to a primary defect in apoptosis or programmed cell death. ALPS is a rare disorder in children characterized by splenomegaly, massive lymphadenopathy, autoimmune phenomena such as thrombocytopenia, neutropenia, haemolytic anaemia and accumulation of double-negative (CD3⁺CD4⁻CD8⁻) T cells in the blood¹,². In the majority of patients ALPS occurs due to inherited mutations in genes encoding proteins of the Fas pathway, which mediates programmed cell death or apoptosis³.

Case report

A one year old boy presented with hepatosplenomegaly, anaemia and neutropenia. His complaints began at seven months of age and were gradually progressive. He was born of a third-degree consanguineous marriage. Physical examination revealed pallor, significant cervical lymphadenopathy, firm hepatomegaly of 2cm and a spleen of 3cm. Developmental status and other systemic examinations were normal. His blood count showed a hypochromic, microcytic anaemia (hemoglobin level of 7 g/dl), thrombocytopenia (platelet count of 19,000/µl) and neutropenia (white blood cell count of 5,500/µl with an absolute neutrophil count of 330), thus indicating pancytopenia. The liver function tests, lipid profile and serum immunoglobulin levels were unremarkable and tuberculin test was negative. Direct and indirect Coombs tests were negative. Bone marrow biopsy showed mild cellular hyperplasia and increased megakaryocytes. Serologic evaluation for infectious diseases such as HIV, EBV, CMV, HCV and HBV were negative. Serum Vitamin B12 levels were high (1900 ng/L). Chest radiography and abdominal ultrasound were unremarkable. Autoimmune markers (ANA and ds DNA) were negative. Immunophenotyping showed normal lymphocytes. Peripheral blood lymphocytes were analyzed by flow-cytometry for double negative T-cells using monoclonal antibodies against blood cell markers. The blood sample showed 5.2% of double negative cells. Lymph node biopsy also revealed reactive B-zone hyperplasia with presence of double negative T cells. Hence, the patient was diagnosed to have ALPS on the basis of:

- Lymphadenopathy with splenomegaly
- Lymph node biopsy showing reactive B-zone hyperplasia with double negative T cells
- Peripheral blood showing raised circulating DNT cells
- Cytopenia

The patient fulfilled two required criteria and two supportive criteria, thus establishing the diagnosis of ALPS. He was treated with oral prednisolone (1mg/kg/day) for a period of two months with a significant decrease in the size of lymph nodes and an increase in platelet count on follow-up.

Discussion

To the best of our knowledge, very few cases of ALPS have been reported in South-East Asia, especially in the Indian subcontinent. The immune response to infectious agents results in the expansion of antigen-specific lymphocytes, some of which could become harmful to the host. The maintenance of proper homeostasis requires that lymphocyte expansion be appropriately balanced by lymphocyte elimination⁴. ALPS is a chronic, nonmalignant lymphoproliferative disorder caused by mutations in the genes that are involved in apoptosis. This impaired apoptosis leads to accumulation of lymphocytes causing lymphadenopathy, autoimmune phenomena and a high risk of developing malignant lymphomas. Most of the patients manifest between six months to 18 years. The most common autoimmune disorder is immune thrombocytopenic purpura (ITP) and haemolytic anaemia. There is also accumulation of phenotypically normal CD3⁺, CD4⁺, CD8⁻ T cells (CD3⁺ DNT).⁵ Autosomal recessive and dominant mutations have been described⁶. The ALPS phenotype is associated with inherited mutations in the CD95 gene (ALPS Type Ia) or the CD95 ligand gene (ALPS Type Ib). In ALPS Type II, a more severe clinical phenotype is presumed to be caused by an undefined inherited
gene defect in the absence of mutations in the CD95 or CD95 ligand genes. ALPS must be suspected in children presenting with autoimmunity and lymphadenopathy. Investigations should include flow cytometric analysis of peripheral blood to look for CD3+ DNT cells and ideally a test for apoptosis. However, demonstration of defective antigen induced apoptosis in cultured activated lymphocytes in vitro requires substantial laboratory support and incurs a significant cost. There are no curative treatment modalities for this entity to date. Initial line of treatment for most patients has been steroids and immunoglobulins with varied responses. Alternative options with pyrimethamine-sulfadoxine and mycofenolate mofetil have shown good response rates (100% clinical response in seven patients and 92% hematomadological response in 13 patients respectively).8,9 Other modalities of immunomodulation with vincristine and Rituximab have also been tried. Bone marrow transplantation has been done successfully in two cases with severe, worsening clinical phenotype.9 Recently, treatment with Sirolimus resulted in complete response in patients with ALPS.10 The diagnostic criteria for ALPS are given below:

**Diagnostic Criteria for ALPS**

**Required Features:**
- Chronic, non-malignant, non-infectious lymphadenopathy and/or splenomegaly lasting at least 6 months
- Elevated CD3+ CD4-/CD8- double-negative (DN) α/β T-cell receptor (TCR) T cells (≥1.5% of total lymphocytes or 2.5% of CD3+ lymphocytes) with normal or elevated lymphocyte count

**Primary Accessory:**
- Lymphocyte apoptosis in 2 separate assays
- A somatic or germline pathogenic mutation in Fas, FasLG or CASP10

**Secondary Accessory:**
- An elevated plasma level of soluble FasL (>200pg/mL) / elevated plasma interleukin-10 levels (>20pg/mL)/ elevated plasma interleukin-18 levels (>500pg/mL) / elevated serum or plasma vitamin B12 levels (>1500 ng/L)
- Typical immune-histochemical findings reviewed by an experienced hematopathologist
- Autoimmune cytopenia (haemolytic anemia, neutropenia, or thrombocytopenia) with an elevated immunoglobulin G level (polyclonal)
- Family history of a non-malignant, non-infectious lymphoproliferation with or without autoimmunity.

Definitive diagnosis of ALPS is based upon the presence of required criteria and one primary accessory criterion. Probable diagnosis is based upon the presence of required criteria and one secondary accessory criterion. ALPS should be suspected in all patients with lymphadenopathy, chronic hepatosplenomegaly and cytopenia.

**Acknowledgements**

The authors thank Dr. Mukesh Desai, Consultant Immuno-hematologist, BJWHC for helping in the diagnosis and Dr. Y K Amdekhar, the Medical Director, BJWHC for permission to publish the case.

**References**


http://dx.doi.org/10.1016/00928674(95)90013-6

http://dx.doi.org/10.1046/j.1365-2141.2002.03357.x

http://dx.doi.org/10.1111/j.1365-2141.2005.05496.x

http://dx.doi.org/10.1038/sj.bmt.1701306

http://dx.doi.org/10.1111/j.1365-2141.2009.07595.x

http://dx.doi.org/10.1182/blood-201004280347